96906 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used Alzheimer's disease; Amyloid plaque core protein
AMYLOID PEPTIDE VARIANTS
#2GENE EDITING-BASED METHOD OF ATTENUATING THE BETA-AMYLOID PATHWAY
#3BIOMOLECULES INVOLVED IN ALZHEIMER'S DISEASE
#4Mouse Model For Alzheimer's Disease And Neurofibrillary Pathology
#5M13 bacteriophages displaying peptide motifs targeting amyloid-beta, methods and uses thereof
#6METHODS FOR TREATING ALZHEIMER'S DISEASE
#7METHODS OF DIAGNOSING AND TREATING ALZHEIMER'S DISEASE
#8WILD-DERIVED MOUSE MODELS OF ALZHEIMER’S DISEASE
#9GENE THERAPY FOR TREATING NEURODEGENERATIVE DISEASES
#10PEPTIDE-HINGE-FREE FLEXIBLE ANTIBODY-LIKE MOLECULE
#11Compositions of Phosphorylated Tau Peptides and Uses Thereof
#12VARIANT NEURODEGENERATIVE DISEASE-ASSOCIATED PROTEIN
#13Multi-Epitope Vaccine for the Treatment of Alzheimer's Disease
#14PROTEIN-BASED ADVANCED WOUND HEALING SYSTEM
#15BIOLOGICAL DEVICES FOR THE DETECTION OF ALZHEIMER'S DISEASE AND CONCUSSIONS AND METHODS OF USE THEREOF
#16SYSTEMS AND METHODS FOR INHIBITING gamma-SECRETASE PRODUCTION OF AMYLOID-beta PEPTIDES
#17MHC IB-MEDIATED ISLET-ANTIGEN-SPECIFIC IMMUNOSUPPRESSION AS A NOVEL TREATMENT FOR TYPE 1 DIABETES
#18MULTIEPITOPE VACCINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE
#19PEPTIDIC INHIBITORS OF AMYLOID SELF- AND CROSS-ASSEMBLY
#20SEQUENCES AND METHODS FOR PRODUCTION OF RECOMBINANT BIOLOGICAL MOLECULES IN VESICLES
#21COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROTEOPATHIES
#22NEURODEGENERATIVE DISORDERS
#23Animal Model With Rapid Onset Of Alzheimer's Amyloid Beta Plaque Pathology
#24METHODS AND COMPOSITIONS FOR MONITORING PHAGOCYTIC ACTIVITY
#25Multi-epitope vaccine for the treatment of Alzheimer's disease
#26MACROCYCLIC MODULATORS OF DISEASE ASSOCIATED PROTEIN MISFOLDING AND AGGREGATION
#27TAU PEPTIDE IMMUNOGEN CONSTRUCTS
#28MICROBIAL PRODUCTION OF POLYMERIC AMYLOID FIBERS
#29IMMUNOGENIC PRODUCTS BASED ON MUTEIN AMYLOID beta (Abeta) AMINO ACID SEQUENCES AND USES THEREOF
#30A GENETICALLY MODIFIED IMMUNODEFICIENT MOUSE EXPRESSING HUMAN OR HUMANIZED APP AND MUTATED HUMAN PSEN1
#31TAU BIOSENSOR CELL LINES
#32ANTI-TAU ANTIBODIES AND USES THEREOF
#33TAU-BINDING ANTIBODIES
#34TREATMENT OF TAUOPATHIES
#35TAU-BINDING ANTIBODIES
#36Multi-epitope vaccine for the treatment of Alzheimer's disease
#37Multi-epitope vaccine for the treatment of Alzheimer's disease
#38N-TERMINAL TRUNCATED PROTOFIBRILS/ OLIGOMERS FOR USE IN THERAPEUTIC AND DIAGNOSTIC METHODS FOR ALZHEIMER'S
#39Multi-epitope vaccine for the treatment of Alzheimer's disease
#40GENE EDITING-BASED METHOD OF ATTENUATING THE BETA-AMYLOID PATHWAY
#41FUSION PROTEIN COMPRISING A BLOOD-BRAIN BARRIER (BBB)-CROSSING SINGLE DOMAIN ANTIBODY FC5, AN IMMUNOGLOBULIN FC FRAGMENT AND A BETA-AMYLOID BINDING POLYPEPTIDE (ABP)
#42TAU MODULATORS AND METHODS AND COMPOSITIONS FOR DELIVERY THEREOF
#43METHODS FOR QUANTIFICATION OF AMYLOID BETA PEPTIDES IN PLASMA BY MASS SPECTROMETRY
#44Heterologous Administration of Tau Vaccines
#45COMPOSITIONS AND METHODS FOR SCREENING 4R TAU TARGETING AGENTS
#46ZINC FINGER PROTEIN TRANSCRIPTION FACTORS FOR REPRESSING TAU EXPRESSION
#47SELF-ASSEMBLED PEPTIDE NANORODS AND USES THEREOF
#48A METHOD OF DECREASING CONCENTRATION OF TAU (T) PROTEIN AND/OR PHOSPHORYLATED TAU (T) PROTEIN
#49Protein variant and composition for treating neurodegenerative disease using the same
#50TAU EPITOPE AND BINDING MOLECULES
#51Multi-Epitope Vaccine for the Treatment of Alzheimer's Disease
#52HIGH AFFINITY VIRAL CAPTURE HUMAN DECOY BASED PROTEINS FOR DETECTION AND PROTECTION AGAINST SARS-CoV-2 AND ZOONOTIC THREATS
#53Cyclic Peptides
#54COMPOSITION AND METHOD FOR TREATING ALZHEIMER'S DISEASE
#55NON-HUMAN ALZHEIMER'S DISEASE MODEL ANIMAL AND METHOD FOR PRODUCING SAME
#56IMMUNOTHERAPEUTIC MODULATION OF AMYLOIDOGENIC DISEASE USING NON-FIBRILLOGENIC, NON-AMYLOIDOGENIC POLYMERIZED PROTEINS AND PEPTIDES
#57STRUCTURE-BASED PEPTIDE INHIBITORS OF ALPHA-SYNUCLEIN AGGREGATION
#58GENE THERAPY FOR NEURODEGENERATIVE DISORDERS
#59TREATING ALZHEIMER'S DISEASE UTILIZING EXTRACORPOREAL RADIOFREQUENCY
#60Novel Molecules for Diagnosis
#61NEW TAU SPECIES
#62PEPTIDE-HINGE-FREE FLEXIBLE ANTIBODY-LIKE MOLECULE
#63Chimeric protein in the treatment of amyloidosis
#64METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISORDERS AND ALZHEIMER'S DISEASE AND IMPROVING NORMAL MEMORY
#65Methods and compositions for monitoring phagocytic activity
#66THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR DEMENTIA
#67TREATMENT OF TAUOPATHIES
#68APPLICATION OF TPK AS A TARGET IN ALZHEIMER'S DISEASE
#69MULTIMERIC PROTEIN DOMAINS FOR MULTIFUNCTIONALITY AND ENHANCED SECRETION OF THERAPEUTIC PROTEINS
#70TREATING ALZHEIMER'S DISEASE
#71DNA VACCINE AGAINST AMYLOID-BETA AND TAU
#72DARPin REAGENTS THAT DISTINGUISH ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE SAMPLES
#73ß-AMYLOID CYCLIC RIBONUCLEIC ACID, POLYPEPTIDE, AND APPLICATION THEREOF
#74GENE THERAPY FOR ALZHEIMER`S DISEASE
#75EXPRESSION OF ANTIGEN-BINDING PROTEINS IN THE NERVOUS SYSTEM
#76AMYLOID CONJUGATE AND USES AND METHODS THEREOF
#77COMPOSITIONS AND METHODS FOR DISASSEMBLING AMYLOID FIBRILS
#78AMYLOID PEPTIDE VARIANTS
#79HUMANIZED AND STABILIZED FC5 VARIANTS FOR ENHANCEMENT OF BLOOD BRAIN BARRIER TRANSPORT
#80Immunotherapeutic compositions for the treatment of Alzheimer's disease
#81Gene editing-based method of attenuating the beta-amyloid pathway
#82AFFINITY SUPPORT AND METHOD FOR TRAPPING SUBSTANCE USING THE SAME
#83PROTEIN-BASED THERAPY AND DIAGNOSIS OF TAU-MEDIATED PATHOLOGY IN ALZHEIMER'S DISEASE
#84Bi-functional anti-tau polypeptides and use thereof
#85Compositions of Phosphorylated Tau Peptides and Uses Thereof
#86ALZHEIMER ABETA PEPTIDE BINDING POLYPEPTIDE
#87INFECTION-INDUCED ENDOTHELIAL AMYLOID COMPOSITIONS AS ANTIMICROBIALS
#88Systems and methods for inhibiting γ-secretase production of amyloid-β peptides
#89Fret-based method to measure seeding activity of misfolded protein species in biological samples
#90Parallel Enzyme Digestion for Protein Biomarker Detection
#91Light-inducible protein aggregation system for modeling proteinopathies and neurodegenerative disorders
#92MUTATED TAU PROTEIN FRAGMENT AND USE THEREOF
#93Human Anti-Tau Antibodies
#94Method for preparing PHFS-like Tau aggregates
#95Peptide complex with immunodulatory and anti-inflammatory function
#96AMYLOSPHEROID (ASPD)-LIKE STRUCTURE AND PHARMACEUTICAL COMPOSITION
#97BIPARTITE MOLECULES AND USES THEREOF IN TREATING DISEASES ASSOCIATED WITH ABNORMAL PROTEIN AGGREGATES
#98Treatment of tauopathies
#99Fibrous proteinaceous networks and methods of use thereof
#100METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISORDERS AND ALZHEIMER'S DISEASE AND IMPROVING NORMAL MEMORY
#101N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
#102Methods of binding amyloid beta protein having pyroglutamate at the third amino acid residue (3pE abeta) in vivo using anti-3pE abeta antibodies or antigen-binding fragments thereof
#103Tau-binding antibodies
#104Tau-binding antibodies
#105HUMAN ISLET AMYLOID POLYPEPTIDE (HIAPP) SPECIFIC ANTIBODIES AND USES THEREOF
#106Tau peptide immunogen constructs
#107Cyclic compound/peptide comprising an A-beta13-16 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-beta13-16 peptide
#108Cyclic compound/peptide comprising an A-beta15-18 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-BETA15-18 peptide
#109Methods for the Treatment and Diagnosis of Alzheimer's Disease and Traumatic Brain Injuries
#110Compositions comprising cyclic peptides derived from an A-beta peptide
#111Anti-Tau antibodies and uses thereof
#112Neurodegenerative disorders
#113Structure-based peptide inhibitors of α-synuclein aggregation
#114Compositions of phosphorylated tau peptides and uses thereof
#115Synthetic beta-amyloid peptides capable of forming stable antigenic oligomers
#116Heterologous administration of tau vaccines
#117Blood cell biomarker for late onset Alzheimer's disease
#118METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF CONFORMATION-SPECIFIC ANTIBODIES
#119AMYLOID CONJUGATE AND USES AND METHODS THEREOF
#120DARPin reagents that distinguish Alzheimer's disease and Parkinson's disease samples
#121HUMANIZED ANTI-TAU(PS422) ANTIBODIES AND METHODS OF USE
#122REGULATING PROTEIN SPONTANEOUS RUPTURES
#123Immunotherapy for Clearing Pathological Tau Conformers
#124Alzheimer Aβ peptide binding polypeptide
#125Methods of detecting pyroglutamate amyloid beta protein (3pE Aβ) using anti-3pE Aβ antibodies
#126THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR DEMENTIA
#127Macrocyclic modulators of disease associated protein misfolding and aggregation
#128STEM CELL MODEL OF APOE GENOTYPE AND Abeta42-DEPENDENT NEURODEGENERATION AND METHODS OF USING THE SAME
#129Methods for the treatment of glaucoma and age-related macular degeneration by a peptide D-TRP-AIB
#130METHODS OF DIAGNOSING AND TREATING ALZHEIMER'S DISEASE
#131RARE PHOSPHORYLATED HIGH MOLECULAR WEIGHT (HMW) TAU SPECIES THAT ARE INVOLVED IN NEURONAL UPTAKE AND PROPAGATION AND APPLICATIONS THEREOF
#132Peptide inhibitors of transcription factor aggregation
#133NEW TAU SPECIES
#134CELL THERAPY COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASE COMPRISING REGULATORY T CELLS AS ACTIVE INGREDIENT
#135Methods for detection of Tau protein aggregation modulating compounds
#136Structure-based peptide inhibitors that target the Tau VQIINK fibrillization segment
#137Methods and compositions for treating neurodegenerative disorders and Alzheimer's Disease and improving normal memory
#138Immunotherapeutic compositions for the treatment of Alzheimer's disease
#139Tau-binding antibodies
#140Transgenic mouse expressing amyloid precursor protein that has olfactory neuron degeneration
#141Fusion protein comprising a blood-brain barrier (BBB)-crossing single domain antibody Fc5, an immunoglobulin Fc fragment and a beta-amyloid binding polypeptide (ABP)
#142Mutant islet amyloid polypeptides with improved solubility and methods for using the same
#143Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
#144Mutated tau protein fragment and use thereof
#145PEPTIDE OR COLLECTION OF PEPTIDES DERIVED FROM AMYLOID PRECURSOR PROTEIN
#146Tau-binding antibodies
#147ABETA VARIANTS, ASSAY, METHOD AND TREATMENT OF ALZHEIMER'S DISEASE
#148Structure-based peptide inhibitors of alpha-synuclein aggregation
#149Human Anti-Tau Antibodies
#150CHIMERIC RECEPTORS AND METHODS OF USE THEREOF
#151Neuroprotective beta amyloid core peptides and peptidomimetic derivatives
#152Therapeutic agents for neurological and psychiatric disorders
#153Treatment of tauopathies
#154Gene editing-based method of attenuating the beta-amyloid pathway
#155Method for screening drug and therapeutic targets used for treating Alzheimer's disease
#156Bi-functional anti-tau polypeptides and use thereof
#157PEPTIDE VACCINE FOR PREVENTION AND IMMUNOTHERAPY OF DEMENTIA OF THE ALZHEIMER'S TYPE
#158Alzheimer's disease animal model
#159Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
#160METHODS AND SYSTEM FOR DETECTING LIVING, NON-DEMENTED PATIENTS WHO HAVE ALZHEIMER'S DISEASE NEUROPATHOLOGY FOR ALZHEIMER'S DISEASE
#161Methods of making gels and films using curli nanofibers
#162Compositions of phosphorylated tau peptides and uses thereof
#163Anti-Tau antibodies and uses thereof
#164Anti-tau antibodies and uses thereof
#165DETECTION OF NEURODEGENERATIVE DISEASES
#166D-enantiomeric peptides derived from D3 and use thereof
#167Method for identifying a modulator of cell survival or plasticity
#168Targeting immunotherapy for amyloidosis
#169CHIMERIC ANTIGEN RECEPTOR MEDIATED CELL TARGETING
#170Method for treating blood, blood products and organs
#171SOLUBLE HIGH MOLECULAR WEIGHT (HMW) TAU SPECIES AND APPLICATIONS THEREOF
#172Human islet amyloid polypeptide (hIAPP) specific antibodies and uses thereof
#173Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
#174C-TERMINAL EPITOPES IN AMYLOID BETA AND CONFORMATIONALLY-SELECTIVE ANTIBODIES THERETO
#175Electrically conductive protein nanofibers and biofilms
#176Ligand-guided phagocytosis based therapy for treatment of Alzheimer's disease and other neurodegenerative diseases
#177N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
#178EPITOPES IN AMYLOID BETA AND CONFORMATIONALLY-SELECTIVE ANTIBODIES THERETO
#179Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
#180CHIRAL CONVERSION OF AMYLOID PROTEINS ASSOCIATED WITH DISEASES
#181Oxidized Aβ peptide
#182Method of identifying novel protein aggregation inhibitors based on chemical kinetics
#183SECRETED PROTEINS
#184Chimeric protein in the treatment of amyloidosis
#185COMPOSITIONS AND METHODS FOR DISASSEMBLING AMYLOID FIBRILS
#186Method of detecting an APP Alzheimer's disease marker peptide in patients with Alzheimer's disease
#187Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
#188DNA molecules encoding antibodies to tau and methods of making thereof
#189PEPTIDE VACCINE FOR PREVENTION AND IMMUNOTHERAPY OF DEMENTIA OF THE ALZHEIMER'S TYPE
#190Tau-binding antibodies
#191Tau-binding antibodies
#192DISRUPTION OF THE INTERACTION BETWEEN AMYLOID BETA PEPTIDE AND DIETARY LIPIDS
#193Methods and agents for treating Alzheimer's disease
#194EFFICIENT PRODUCTION OF PEPTIDES
#195Methods for the treatment and diagnosis of Alzheimer's disease and traumatic brain injuries
#196Structure-based peptide inhibitors of P53 aggregation as a new approach to cancer therapeutics
#197DNA vaccine against amyloid-β and tau
#198Tau modulators and methods and compositions for delivery thereof
#199BIOMOLECULES INVOLVED IN ALZHEIMER'S DISEASE
#200Method for clinically and pathologically monitoring Alzheimer's disease through concentration of amyloidbeta in plasma
#201Method for producing myocardial cells using synthetic peptide
#202Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
#203Synthetic beta-amyloid peptides capable of forming stable antigenic oligomers
#204Cyclic, amyloid beta-binding peptides and the use thereof
#205Cell-directed synthesis of multifunctional nanopatterns and nanomaterials
#206AMYLOID-BETA BINDING PROTEINS
#207Bipartite molecules and uses thereof in treating diseases associated with abnormal protein aggregates
#208METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF CONFORMATION-SPECIFIC ANTIBODIES
#209Specific amyloid beta binding peptides and the use of same for treating and diagnosing alzheimer's dementia
#210Method for assisting detection of alzheimer'S disease or mild cognitive impairment
#211A PEPTIDE OR COLLECTION OF PEPTIDES DERIVED FROM AMYLOID PRECURSOR PROTEIN
#212ALZHEIMER ABETA PEPTIDE BINDING POLYPEPTIDE
#213Treatment agent for cognitive impairment induced by amyloid beta-protein, therapeutic agent for alzheimer's disease, and treatment method and pathological analysis method related to these
#214Method of immunization for reducing toxic damaged caused by oligomeric form of the amyloid-beta protein with stable amyloid beta monomers and oligomers
#215Yeast cells expressing amyloid beta and uses therefor
#216Immunotherapy for Clearing Pathological Tau Conformers
#217Human Anti-Tau Antibodies
#218Stable amyloid beta monomers and oligomers
#219Class of therapeutic protein based molecules
#220Chiral Substituted Amyloid Beta Peptides
#221Peptide-hinge-free flexible antibody-like molecule
#222METHODS AND COMPOSITIONS FOR DISEASES ASSOCIATED WITH AMYLOIDOSIS
#223D-enantiomeric peptides derived from D3 and use thereof
#224β-sheet breaker peptide used for preventing and/or treating alzheimer's disease
#225Alzheimer's Disease
#226Targeting immunotherapy for amyloidosis
#227TREATMENT OF TAUOPATHIES
#228Reduction of amyloid beta peptide production via modification of the APP gene using the CRISPR/Cas system
#229AGENTS USEFUL IN DIAGNOSTIC AND THERAPY OF BETA-AMYLOID AGGREGATION RELATED DISORDERS AND SCREENING METHODS
#230Pig model for diabetes
#231Bipartite molecules and uses thereof in treating diseases associated with abnormal protein aggregates
#232Methods, compositions, diagnostics and assays for the treatment of Alzheimer's disease
#233Method for treating blood, blood products and organs
#234COMPOSITIONS AND METHODS RELATED TO TAUOPATHY
#235Humanized anti-Tau(pS422) antibodies and methods of use
#236Expression cassette and vector comprising Alzheimer's disease-related mutant genes and cell line transformed by means of same
#237Immunotherapeutic compositions for the treatment of alzheimer's disease
#238METHODS AND COMPOSITIONS RELATED TO AMYLOID-BETA-42 OLIGOMERS
#239Immunoassay standards and measurement of clinical biomarkers using intra-assay calibration standards
#240Methods and compositions for treating neurodegenerative disorders and alzheimer's disease and improving normal memory
#241Chimeric peptide that interacts with cell membrane gangliosides
#242Methods for the treatment of glaucoma and age-related macular degeneratiion by a peptide D-TRP-AIB
#243Amyloid precursor protein (APP) based Ã#-secretase inhibitor peptides, and methods of use
#244SAA-domain-specific antibodies and peptide antagonists and use thereof to treat inflammatory diseases
#245Anti-Aβ globulomer 4D10 antibodies
#246Human islet amyloid polypeptide (HIAPP) specific antibodies and uses thereof
#247POLYMERS CONTAINING MULTIVALENT AMYLOID-BETA-BINDING D-PEPTIDES AND THEIR USE
#248Tau peptides, anti-tau antibodies, and methods of use thereof
#249Method for inducing differentiation of pluripotent stem cells into endodermal cells
#250Method for treating amyloid disease
#251Compositions and Methods for Treating Alzheimer's Disease
#252CHIMERIC PROTEIN IN THE TREATMENT OF AMYLOIDOSIS
#253Alzheimer's disease animal model
#254Cells expressing apolipoprotein E and uses thereof
#255Amyloid protofibril antibodies and methods of use thereof
#256Targeting immunotherapy for amyloidosis
#257Oligomer-specific amyloid beta epitope and antibodies
#258Methods of synthesizing γ-aapeptides, γ-aapeptide building blocks, γ-aapeptide libraries, and γ-aapeptide inhibitors of Aβaggregates
#259EFFICIENT PRODUCTION OF PEPTIDES
#260HSP20 inhibits amyloidogenesis and neurotoxicity
#261Class of therapeutic protein based molecules
#262Biological devices and methods of use thereof for the study and control of alzheimer's disease
#263Method for detecting indicators for determining diseases
#264Compositions and methods related to tauopathy
#265Methods for the expression of peptides and proteins
#266Oxidized Aβ peptide
#267Agents for preventing and treating HIV and other viral infections
#268Diagnostic kit for diagnosis of abnormal protein aggregation- or misfolding-related diseases using dissociation of protein aggregates
#269Amyloid β(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
#270PEPTIDE VACCINE FOR PREVENTION AND IMMUNOTHERAPY OF DEMENTIA OF THE ALZHEIMER'S TYPE
#271Structure-based peptide inhibitors of P53 aggregation as a new approach to cancer therapeutics
#272Methods and agents for treating Alzheimer's disease
#273Immunoassay standards and measurement of tau using intra-assay calibration standards
#274Composition and method for preventing or treating a tauopathy
#275Amyloidosis-inhibiting polypeptides and their use
#276Polynucleotides encoding anti-amyloid beta monoclonal antibodies
#277IMMUNOGENIC PRODUCTS BASED ON MUTEIN AMYLOID beta (Abeta) AMINO ACID SEQUENCES AND USES THEREOF
#278Immunotherapy for clearing pathological tau conformers
#279Amyloid beta expression constructs and uses therefor
#280Methods and compositions for treating neurodegenerative disorders and alzheimer's disease and improving normal memory
#281Peptides for the treatment and early diagnosis of Alzheimer's disease and other tauopathies
#282Method for treating blood, blood products and organs
#283Vaccine for treatment of tautopathy
#284QUANTIFICATION OF TAU IN BIOLOGICAL SAMPLES BY IMMUNOAFFINITY ENRICHMENT AND MASS SPECTROMETRY
#285Human anti-tau antibodies
#286Compositions and methods related to diseases associated with deposits of amyloid, tau, and alpha-synuclein
#287Amyloid-beta binding proteins
#288Human islet amyloid polypeptide (hIAPP) specific antibodies and uses thereof
#289Affinity support and method for trapping substance using the same
#290Peptide-hinge-free flexible antibody-like molecule
#291Antibodies obtainable using supramolecular constructs
#292THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR DEMENTIA
#293Humanized anti-Tau(pS422) antibodies and methods of use
#294Method for treating amyloid disease
#295Compounds and methods for inhibiting cell death
#296Conformationally dynamic peptides
#297Gene therapy for Alzheimer's and other neurodegenerative diseases and conditions
#298Polymers containing multivalent amyloid-beta-binding D-peptides and their use
#299Cell-directed synthesis of multifunctional nanopatterns and nanomaterials
#300Biochemical markers for neurodegenerative conditions